Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 33 Small Cell Lung Carcinoma 16 Breast Neoplasms 13 Sarcoma 10 Carcinoma, Hepatocellular 8 Esophageal Squamous Cell Carcinoma 7 Lung Neoplasms 6 Triple Negative Breast Neoplasms 5 Ovarian Neoplasms 5 Neoplasms 5 Carcinoma 5 Stomach Neoplasms 4 Pheochromocytoma 4 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Nasopharyngeal Carcinoma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Ovarian Epithelial 4 Thyroid Neoplasms 3 Recurrence 3 Paraganglioma 3 NSCLC 3 Glioma 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Platinum-resistant Ovarian Cancer 2 Ovarian Diseases 2

Interventions

pembrolizumab 3 apatinib 3 Magnetic Resonance Spectroscopy 3 lenvatinib 2 Specimen Handling 2 Nivolumab 2 Imatinib Mesylate 2 Epirubicin 2 Cisplatin 2 Carboplatin 2 Axitinib 2 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 regorafenib 1 gallium 68 PSMA-11 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 anlotinib 1 amivantamab 1 Tretinoin 1 Sunitinib 1 Radiation 1 Pemetrexed 1 Nelfinavir 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Lutetium-177 1 Lutetium 1 Ipilimumab 1 Glutamate Carboxypeptidase II 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Adenoid Cystic × anlotinib × Clear all

NCT07616141 2026-06-01

NAET4-SNACC

Eye & ENT Hospital of Fudan University

Phase 2 Not yet recruiting

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡